Welcome to our dedicated page for NUGENE INTERNATIONAL news (Ticker: NUGN), a resource for investors and traders seeking the latest updates and insights on NUGENE INTERNATIONAL stock.
NuGene International, Inc. (symbol: NUGN), based in Irvine, California, is a dynamic leader in the skincare and hair care industries in the United States. The company develops and markets a wide range of personalized skincare products, including universal cream, serums for eyes and facial use, gel, and face wash products. In addition to skincare, NuGene offers an array of hair care products such as regenerative shampoos and conditioners, and specialized anti-hair loss serums. NuGene is also engaged in pioneering research and the formulation of a topical burn cream designed for effective burn treatment.
The company caters to multiple segments including wholesale distributors, physicians, and direct consumers, showcasing its ability to penetrate diverse market channels. NuGene International has shown an unwavering commitment to cutting-edge biotechnology, bringing innovative solutions from its laboratory to the consumer's shelf.
Recently, NuGene International, Inc. reported significant achievements that underline its growth trajectory. These include the approval of its Form 10 by the Securities and Exchange Commission (SEC), marking a key milestone towards becoming a fully reporting public entity with aspirations to list on major exchanges like NASDAQ. This approval signifies the company’s dedication to transparency and regulatory compliance while providing prospective investors with comprehensive data to inform their investment decisions.
Financially robust, NuGene boasts a portfolio exceeding $46 million in total assets. The company has made notable strides in expanding its footprint across Europe and Africa, demonstrating its global reach and influence. Additionally, the company's subsidiary, BOXO Productions, has been instrumental in driving revenue growth through successful movie and TV projects.
NuGene International continues to innovate and develop, investing in advancements in robotics and AI, further enhancing its competitive edge. This diversified approach, coupled with strategic acquisitions and partnerships, positions NuGene as a formidable player in the industry.
NuGene International, Inc./Livento Group, Inc. (OTC Pink: NUGN) has initiated the Public Offering process for its logistics project, EuroDot. With final stages underway, legal and financial documents are being prepared for a Reg A listing on OTC Markets. Livento Group aims to attract U.S. investors for future acquisitions, targeting revenues of $50 million by 2024 from two profitable acquisition targets, one with $14 million and another with $20 million in revenues, respectively. Initial share price for investors is set at $0.5. A detailed timeline and further financial disclosures are expected in the coming weeks.
NuGene International, Inc./Livento Group (OTC Pink: NUGN) has signed a binding Letter of Intent to acquire a Software Engineering Company specializing in AI and Robotics. The deal is expected to finalize in January 2023 and aims to enhance Livento's business portfolio. The target company is projected to generate $400,000 in revenue for 2023 with a 50% YOY increase. Additionally, Livento plans to leverage available EU grants of $750,000 to support the acquisition's growth. The acquisition is anticipated to provide positive cash flow from day one.
FAQ
What is the current stock price of NUGENE INTERNATIONAL (NUGN)?
What is the market cap of NUGENE INTERNATIONAL (NUGN)?
What does NuGene International, Inc. specialize in?
Where is NuGene International, Inc. located?
What are some of the products offered by NuGene International?
Who are the primary customers of NuGene International?
What recent achievements has NuGene International, Inc. reported?
What are some key financial metrics for NuGene International, Inc.?
What are NuGene International’s recent market expansions?
What is BOXO Productions?
Is NuGene International involved in any emerging technologies?
How can I find more information about NuGene International and its subsidiaries?
